To be fair $1 billion is standard costs of development and commercialisation for drugs and vaccines.
Ten years is about the lead time for biotechs.
It's an expensive business because ensuring safety and proving of clinical outcomes is inherently an exacting matter.
I do think the FDA have been cumbersome but that's the nature of bureaucracies. They've issued a report on their recognised need to reform and be more responsive. SI is an advisor to the FDA. They did respond by creating new protocols for stem cell trials.
There aren't conspiracies everywhere but there are vested interests, no doubt about that.
But I agree that MSB is a winner. No doubt about that.
MSB Trading - 2020, page-7185
-
- There are more pages in this discussion • 15,976 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.010(0.69%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.46 | $1.49 | $1.44 | $3.472M | 2.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12398 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 5440 | 3 |
View Market Depth
| Last trade - 16.10pm 21/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |